Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput. Because of this, ion channels remain an underrepresented target class for drug discovery.
The advent of higher throughput automated electrophysiology systems changed the face of ion channel drug discovery. Since the inaugural “Drug Discovery for Ion Channels” satellite meeting, there have been many advances in ion channel drug discovery including new instrumentation and techniques. For this year, we propose to continue the “Satellite Meeting” tradition at the Biophysical Society Annual Meeting and review the advances ion channel drug discovery.
This year’s meeting will highlight presentations from drug discovery companies, companies that provide ion channel services to drug discovery companies and companies that provide products to ion channel drug discovery companies, as well as other speakers in the field of ion channel drug discovery, including several academic speakers.
8:00 AM
|
Registration and Coffee |
8:30 AM |
Chris Mathes, Metrion Biosciences, USA
Welcome and Opening Remarks |
Session I |
Daniel Sauter, Sophion Bioscience, USA |
8:45 AM - 9:30 AM |
David Adams, University of Wollongong, Australia
GABA B Receptor Modulation of Membrane Excitability in Human Pluripotent Stem Cell-Derived Sensory Neurons by Baclofen and α-conotoxin Vc1.1 |
9:30 AM - 10:00 AM |
John Gilchrist, Latigo Bioterapeutics, USA
Diminazene Reveals Unexpected ASIC Biology |
10:00 AM - 10:30 AM |
Jun Chen, Genentech, USA
Subtype-selective Modulation and Rescue of HCN1 Channel Mutants |
10:30 AM - 11:00 AM
|
Coffee Break |
Session II |
Jean Francois Rolland, Axxam, Italy |
11:00 AM - 11:30 AM |
Stephan Pless, University of Copenhagen, Denmark
Targeting Ion Channels with De Novo Designed Mini Proteins |
11:30 AM - 12:00 PM |
Fernanda Laezza, University of Texas, USA
Mining the Voltage-Gated Na+ Channel for Neurotherapeutics Development |
12:00 PM - 12:30 PM |
Jeremiah Osteen, Vertex Pharmaceuticals, USA
Title to be Announced |
12:30 PM - 1:30 PM |
Lunch |
Session III |
Chris Mathes, Metrion Biosciences, USA, Chair
|
1:30 PM - 2:00 PM |
Jose Matta, Rapport Therapeutics, USA
Targeting AMPA Receptors in Complex with TARP-g8 for Epilepsy and Pain
|
2:00 PM - 2:30 PM |
Xi Huang, Toronto Hospital for Sick Children, Canada
Targeting Potassium Channels in Brain Tumor-Initiating Cells |
2:30 PM – 3:00 PM |
Victoria Assimon, Maze Therapeutics, USA
A Small Molecule Inhibitor of APOL1 Attenuates Albuminuria in a Mouse Model of APOL1 Kidney Disease |
3:00 PM - 3:30 PM |
Coffee Break |
Session IV |
Alison Obergrussberger, Nanion, Germany, Chair |
3:30 PM - 400 PM |
Kris Kahlig, Praxis Precision Medicines, USA
Dynamic Action Potential Clamp for the Functional Classification of SCN2A Variants |
4:00 PM - 4:30 PM |
Jose Mercado, DSM Firmenich, USA
Scrambling Mosquito Olfaction to Deter the Buzzing Menace |
4:30 PM - 5:00 PM |
Nina Ottossen, Linkoping University, Sweden
Title to be Announced |
5:00 PM - 5:15 PM |
Alison Obergrussberger, Nanion, Germany
Closing Remarks |
Sponsored by: